Press release
Monopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical Operations
Laura Kelly’s Extensive Experience to Benefit Monopar’s Phase 2b/3 VOICE Trial WILMETTE, Ill., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.
About this update from Monopar Therapeutics Inc.
[{"type":"text","content":"Laura Kelly’s Extensive Experience to Benefit Monopar’s Phase 2b/3 VOICE Trial\nWILMETTE, Ill., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Laura Kelly as Director of Clinical Operations. Ms. Kelly will be responsible for managing Monopar’s clinical programs, including the recently launched Phase 2b/3 VOICE trial for the Company’s lead drug candidate Validive®. Ms. Kelly brings a wealth of clinical research experience, including oncology and the execution of Phase 1 through Phase 4 clinical trials, to the Monopar team. Prior to Monopar, Ms. Kelly served in strategic and clinical operation leadership roles at Merck/EMD Serono, AbbVie, Abbott Labs, and Amgen. “The addition of Laura to the team comes at an ideal time, given the rapid ramp-up in development efforts resulting from the positive progression of our clinical programs,” said Chandler Robinson, MD, Chief Executive Officer of Monopar. “She will be a valuable contributor not only to our Validive clinical trial, but also to our camsirubicin clinical program and MNPR-101 as it moves toward an IND.” “We are very pleased to welcome Laura to the team,” said Andrew Mazar, PhD, Chief Scientific Officer of Monopar. “Her extensive experience in clinical operations combined with strong leadership skills should allow her to make an immediate impact on the timely enrollment and execution of our clinical trials.” About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19. For more information, visit: www.monopartx.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are \"forward-looking statements\" within the meaning...